Cost-utility analysis of abatacept in rheumatoid arthritis in Italy

Por Simona de Portu, Lorenzo Giovanni Mantovani, Ignazio Olivieri
Publicado em 2008-03-01

The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis

Por Paolo Angelo Cortesi, Damiano Paolicelli, Marco Capobianco, Paolo Cozzolino, Lorenzo Giovanni Mantovani
Publicado em 2019-07-01

Letter to the editor: Clinical Use, Quality of Life and Cost-Effectiveness of Spinal Cord Stimulation Used to Treat Patients with Failed Back Surgery Syndrome

Por Luciana Scalone, Lorenzo Giovanni Mantovani, Angelo Lavano, Amedeo Costantini, Gianpaolo Fortini, Furio Zucco
Publicado em 2017-08-01

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.

Por Paolo Angelo Cortesi, Ippazio Cosimo Antonazzo, Claudio Gasperini, Mihaela Nica, Daniela Ritrovato, Lorenzo Giovanni Mantovani
Publicado em 2022-01-01

[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]

Por Gianluca Furneri, Laura Santoni, Chiara Marchesi, Sergio Iannazzo, Paolo Angelo Cortesi, Achille Patrizio Caputi, Lorenzo Giovanni Mantovani
Publicado em 2016-06-01

Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.

Por Paolo Angelo Cortesi, Lucia Sara D'Angiolella, Renato Vellucci, Massimo Allegri, Giuseppe Casale, Carlo Favaretti, Flavia Kheiraoui, Giancarlo Cesana, Lorenzo Giovanni Mantovani
Publicado em 2017-01-01